The American Journal of Human Genetics, Volume 94 Supplemental Data

Progesterone Antagonist Therapy

in a Pelizaeus-Merzbacher Mouse Model

Thomas Prukop, Dirk B. Epplen, Tobias Nientiedt, Sven P. Wichert, Robert Fledrich, Ruth M. Stassart, Moritz J. Rossner, Julia M. Edgar, Hauke B. Werner, Klaus-Armin Nave, and Michael W. Sereda




Figure S1: *Plp1* mRNA Expression in Sciatic Nerve. RT-PCR analysis from sciatic nerve demonstrated 1.3 ± 0.01 -fold upregulation of *Plp1* mRNA expression after Progesterone treatment for 7 weeks in wildtype rats. mRNA expression in the placebo treated wildtype group was set to 1.0 ± 0.01 -fold. * = p<0.05, shown mean ± SEM.




Figure S2: mRNA Expression of Enzymes Involved in the Cholesterol Synthesis Pathway in Total Brains. RT-PCR analysis from total brain demonstrated reduced mRNA expression for enzymes involved in the cholesterol synthesis pathway which was not affected by Lonaprisan treatment. This referred to *Hmgcr* (*HMG-CoA reductase*; A), *Fdft1* (*farnesyl-diphosphate farnesyltransferase 1*; B), *Mvd* (*mevalonate decarboxylase*; C) and *Lss* (*lanosterol synthase*; D) in placebo-treated PMD (0.86±0.05-, 0.58±0.02-, 0.64±0.03-and 0.62±0.05-fold, respectively) and Lonaprisan-treated PMD mice (0.79±0.03-, 0.61±0.02-, 0.64±0.06- and 0.62±0.02-fold, respectively). Wildtype mRNA expression was set to 1.0-fold (±0.04, ±0.04, ±0.16 and ±0.08, respectively). ns = not significant, * = p<0.05, *** = p<0.001, shown mean ± SEM.